Year: 2022
Type: article
Abstract: Ivermectin, an FDA-approved antiparasitic drug, has been reported to have in vitro activity against SARS-CoV-2. An increasing off-label use of Ivermectin for COVID-19 has been reported. We here assessed the effect of Ivermectin in Syrian hamsters infected with the SARS-CoV-2 Beta (B.1.351) variant. Infected animals received a clinically relevant dose of Ivermectin (0.4 mg/kg subcutaneously dosed) once daily for four consecutive days after which the effect was quantified. Ivermectin monotherapy did not reduce lung viral load and even significantly worsened the SARS-CoV-2-induced lung pathology. Additionally, it did not potentiate the activity of Molnupiravir (Lagevrio ™ ) when combined with this drug. This study contributes to the growing body of evidence that Ivermectin does not result in a beneficial effect in the treatment of COVID-19. These findings are important given the increasing, dangerous off-label use of Ivermectin for the treatment of COVID-19.
Source: Microorganisms
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,315
Awards: Katholieke Universiteit Leuven - to screen Reframe library against Covid-19, G2594633648, G2605422190, G27526698, Corona Accelerated R&D in Europe, G5977900945, G6122222817, G6305477373, DEVELOPMENT AND USE OF RELEVANT HAMSTER AND MOUSE SARS-COV-2 INFECTION MODELS TO AID IN THE DESIGN OF THERAPEUTIC AND PROPHYLACTIC OPTIONS FOR COVID-19, G7905289576, Swift COronavirus therapeutics REsponse, G8471316792, G8796584861, G8983293788
OpenAlex ID: W4225660542